Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Maen Hussein1 Florida Cancer Specialists, Leesburg, FL, USACorrespondence[email protected]

Marina Maglakelidze2 LLC Arensia Exploratory Medicine, Tbilisi, Georgia

Donald A Richards3 Texas Oncology-Tyler, US Oncology Research, Tyler, TX, USA

Marielle Sabatini4 Saint Leon Hospital, Bayonne, France

Todd A Gersten5 Florida Cancer Specialists, West Palm Beach, FL, USA

Keith Lerro6 Regional Medical Oncology Center, Wilson, NC, USA

Ivan Sinielnikov7 Volyn Regional Oncology Center, Lutsk, Ukraine

Alexander Spira8 Virginia Cancer Specialists, Fairfax, VA, USA;9 US Oncology Research, The Woodlands, TX, USA

Yili Pritchett10 G1 Therapeutics, Inc., Research Triangle Park, NC, USA

Joyce M Antal10 G1 Therapeutics, Inc., Research Triangle Park, NC, USA

Rajesh Malik10 G1 Therapeutics, Inc., Research Triangle Park, NC, USA

J Thaddeus Beck11 Highlands Oncology Group, Fayetteville, AR, USA

Your download is now in progress and you may close this window